‼️Preprint‼️ CD22 CAR Ts are cooked - time to move on to CD72. Adila Izgutdina and fantastic collaborators show CD72 is likely a better second-line antigen than CD22 for CD19-refractory B-ALL/B-NHL. Excited to bring CD72 “nanoCARs” to the clinic @ucsfhealth.bsky.social. www.biorxiv.org/content/10.1...
biorxiv.org
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies
Background: Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, for most CAR T targets it is observed that low surface antigen d...
